Ángela González-Pérez

Ángela González-Pérez


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2024 in Cells
Verified
Journal Article
Open access
PDF file
MGM Elena Gonzalez-Alvarez
M Elena Gonzalez-Alvarez
Victor Riquelme AguadoVictor Riquelme Aguado
Victor Riquelme Aguado
ÁGÁngela González-Pérez
Ángela González-Pérez
RMRosa Murillo-Llergo
Rosa Murillo-Llergo
MMMaría Manjón-Olmedillas
María Manjón-Olmedillas
Jorge Hugo VillafañeJorge Hugo Villafañe
Jorge Hugo Villafañe
Background: Fibromyalgia (FM) is characterized by chronic pain and a complex array of symptoms, with neuroinflammation implicated in its pathophysiology. Methods: This study aimed to explore the association between neuroinflammation, measured through interleukin levels (IL-1, IL-6, IL-8), and clinical outcomes in FM patients. Using a cross-sectional study design, blood levels of these interleukins were correlated with pain severity and disability, assessed via the Fibromyalgia Impact Questionnaire (FIQ) and pain measures. Results: Results indicated that IL-6 and IL-8 may particularly serve as biomarkers for pain severity and disability in FM patients, showing significant associations with worse clinical outcomes. Elevated IL-8 levels, for instance, correlated strongly with increased pain perception and higher disability scores. Conclusions: These findings suggest that specific interleukins are not only elevated in FM but are actively involved in the modulation of pain and disability, underscoring the role of systemic neuroinflammation in the clinical severity of FM. This study contributes to a deeper understanding of the inflammatory mechanisms in FM and underscores the potential of targeting interleukins in therapeutic strategies.